Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.52 |
| ▸ | HPGD | P15428 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30197915 | 1.00 | HSD17B10 (0.52) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL20097950 | 0.90 | HSD17B10 (0.43) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL14769312 | 0.89 | SIRT1 (0.46) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL31046816 | 0.84 | TSHR (0.41) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL16233577 | 0.83 | CYP3A4 (0.47) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL29433374 | 0.76 | HSD17B10 (0.44) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL11655514 | 0.75 | ACLY (0.49) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL11653139 | 0.74 | MCL1 (0.47) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL11153102 | 0.73 | CYP3A4 (0.43) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL11654816 | 0.73 | HPGD (0.43) | HSD17B10HPGDTSHRMAPK1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3404665-B1 | SYSTEMS AND METHODS FOR AGGREGATION OF AUTOMATICALLY GENERATED LABORATORY TEST RESULTS | MEDIAL RES LTD (IL) | 2024-03-06 | — | — | EP | claimed |
| EP-3637235-B1 | DISPLAY DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-08-30 | — | — | EP | claimed |
| EP-4073249-A1 | MODIFIED GUIDE RNAS FOR GENE EDITING | Intellia Therapeutics, Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| EP-4744062-A2 | SYSTEMS AND METHODS FOR MEDICAL IMAGING GATEWAYS | Alara Imaging Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260105918-A1 | Identity Authentication System Using Enhanced Phonetic Distance Measurement | DENIM HEALTH LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12577311-B2 | Chimeric antigen receptor factories and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4690233-A1 | ARTIFICIAL INTELLIGENCE (AI) TO ASSIST DATA COMPLETENESS CHECK AND IMPROVE RADIOLOGY WORKFLOW EFFICIENCY | Koninklijke Philips N.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| US-20260024649-A1 | ACTIONABLE VISUALIZATION BY OVERLAYING HISTORICAL DATA ON A REAL-TIME IMAGE ACQUISITION WORKFLOW OVERVIEW | KONINKLIJKE PHILIPS NV (NL) | 2026-01-22 | — | — | US | disclosed |
| US-20260018282-A1 | CAREGIVER ASSISTANCE SYSTEM | STRYKER CORP (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4676483-A1 | IMPROVED LINKER-PAYLOADS FOR ANTIBODY CONJUGATION, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF | OBI Pharma, Inc. (TW) | 2026-01-14 | — | — | EP | disclosed |
| US-20260007554-A1 | PATIENT SUPPORT APPARATUS SYSTEM | STRYKER CORP (US) | 2026-01-08 | — | — | US | disclosed |
| US-20160151379-A1 | COMBINATION THERAPIES FOR MALARIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-02 | — | — | US | disclosed |
| US-20160137982-A1 | P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION | TAMPEREEN YLIOPISTO (FI) | 2016-05-19 | — | — | US | disclosed |
| EP-2834349-B1 | P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION | TAMPEREEN YLIOPISTO (FI) | 2016-04-20 | — | — | EP | disclosed |
| EP-2834349-A1 | P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION | Tampereen Yliopisto (FI) | 2015-02-11 | — | — | EP | disclosed |
| WO-2015006752-A1 | COMBINATION THERAPIES FOR MALARIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006753-A2 | THERAPIES FOR DISEASES CAUSED BY ARTHROPOD-BORNE PARASITES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014202837-A1 | P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION | TAMPEREEN YLIOPISTO (FI) | 2014-12-24 | — | — | WO | disclosed |
| US-20130064799-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-03-14 | — | — | US | disclosed |
| WO-2012166973-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260018282-A1 | CAREGIVER ASSISTANCE SYSTEM | ITGB6, ITGA6, SET | HSD17B10 3146/4885HPGD 3159/4885TSHR 1622/4885 |
| US-20260024649-A1 | ACTIONABLE VISUALIZATION BY OVERLAYING HISTORICAL DATA ON A REAL-TIME IMAGE ACQUISITION WORKFLOW OVERVIEW | MOK, RAD1, TNNT2 | HSD17B10 3691/4885HPGD 4100/4885TSHR 583/4885 |
| US-20260007554-A1 | PATIENT SUPPORT APPARATUS SYSTEM | CNTN1, ITGA8, HTR3D | HSD17B10 3957/4885HPGD 4183/4885TSHR 72/4885 |
| US-12577311-B2 | Chimeric antigen receptor factories and methods of use thereof | IGSF11, CD74, TNFRSF9 | HSD17B10 971/4885HPGD 4380/4885TSHR 538/4885 |
| US-20260105918-A1 | Identity Authentication System Using Enhanced Phonetic Distance Measurement | NSUN3, NOTCH3, TIMM9 | HSD17B10 4031/4885HPGD 3646/4885TSHR 642/4885 |
| US-20130064799-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | HIPK2, HIPK3, HIPK1 | HSD17B10 2865/4885HPGD 4447/4885TSHR 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.